Cerity Partners LLC Bluebird Bio, Inc. Transaction History

Cerity Partners LLC

$44.7 Billion
Q3 2024

A detailed history of Cerity Partners LLC transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Cerity Partners LLC holds 89,694 shares of BLUE stock, worth $823,390. This represents 0.0% of its overall portfolio holdings.

Number of Shares

89,694

Previous 82,480 8.75%

Holding current value

$823,390

Previous $80,000 42.5%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$0.47 - $1.35 $3,390 - $9,738	7,214 Added 8.75%	89,694 $46,000
Q2 2024 Aug 13, 2024	BUY	$0.85 - $1.26 $10,912 - $16,175	12,838 Added 18.43%	82,480 $80,000
Q1 2024 May 14, 2024	BUY	$0.91 - $1.75 $9,117 - $17,533	10,019 Added 16.8%	69,642 $89,000
Q4 2023 Jan 26, 2024	BUY	$1.32 - $4.83 $78,702 - $287,979	59,623 New	59,623 $82,000
Q2 2023 Aug 14, 2023	BUY	$2.79 - $5.03 $27,900 - $50,300	10,000 Added 50.96%	29,623 $97,000
Q4 2022 Feb 15, 2023	BUY	$5.77 - $8.49 $52,062 - $76,605	9,023 Added 85.12%	19,623 $135,000
Q3 2022 Nov 10, 2022	SELL	$3.75 - $7.39 $750 - $1,478	-200 Reduced 1.85%	10,600 $67,000
Q2 2022 Aug 10, 2022	SELL	$2.94 - $5.23 $5,544 - $9,863	-1,886 Reduced 14.87%	10,800 $45,000
Q1 2022 Apr 25, 2022	BUY	$4.07 - $10.6 $7,476 - $19,472	1,837 Added 16.93%	12,686 $62,000
Q4 2021 Feb 14, 2022	BUY	$8.96 - $16.31 $97,207 - $176,947	10,849 New	10,849 $108,000
Q3 2021 Oct 25, 2021	SELL	$11.24 - $21.0 $90,594 - $169,260	-8,060 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$18.04 - $22.09 $180 - $220	10 Added 0.12%	8,060 $258,000
Q1 2021 Aug 11, 2021	BUY	$16.59 - $33.89 $22,396 - $45,751	1,350 Added 20.15%	8,050 $243,000
Q1 2021 May 12, 2021	SELL	$16.59 - $33.89 $1,426 - $2,914	-86 Reduced 1.27%	6,700 $202,000
Q4 2020 Feb 11, 2021	BUY	$27.5 - $37.92 $26,427 - $36,441	961 Added 16.5%	6,786 $294,000
Q3 2020 Nov 12, 2020	BUY	$34.44 - $43.75 $6,405 - $8,137	186 Added 3.3%	5,825 $314,000
Q2 2020 Aug 14, 2020	BUY	$27.12 - $45.97 $244 - $413	9 Added 0.16%	5,639 $344,000
Q1 2020 May 14, 2020	SELL	$26.16 - $63.5 $3,662 - $8,890	-140 Reduced 2.43%	5,630 $259,000
Q4 2019 Feb 14, 2020	BUY	$46.96 - $61.67 $10,894 - $14,307	232 Added 4.19%	5,770 $506,000
Q3 2019 Oct 30, 2019	BUY	$59.47 - $93.1 $2,259 - $3,537	38 Added 0.69%	5,538 $508,000
Q2 2019 Aug 14, 2019	SELL	$75.84 - $105.21 $8,569 - $11,888	-113 Reduced 2.01%	5,500 $700,000
Q1 2019 May 14, 2019	BUY	$64.44 - $104.11 $773 - $1,249	12 Added 0.21%	5,613 $883,000
Q4 2018 Feb 06, 2019	BUY	$59.1 - $93.26 $182,619 - $288,173	3,090 Added 123.06%	5,601 $556,000
Q3 2018 Nov 15, 2018	BUY	$88.86 - $117.49 $88,860 - $117,490	1,000 Added 66.18%	2,511 $367,000
Q2 2018 Aug 15, 2018	SELL	$99.64 - $127.59 $896 - $1,148	-9 Reduced 0.59%	1,511 $237,000
Q1 2018 May 15, 2018	BUY	$105.8 - $150.94 $160,816 - $229,428	1,520 New	1,520 $260,000
Q4 2017 Feb 14, 2018	SELL	$81.25 - $130.7 $140,318 - $225,718	-1,727 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$57.74 - $91.42 $99,716 - $157,882	1,727	1,727 $237,000

Others Institutions Holding BLUE

# of Institutions

150

Shares Held

63.4M

Call Options Held

264K

Put Options Held

428K

View Full List

About bluebird bio, Inc.

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $708M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

More about BLUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cerity Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cerity Partners LLC with notifications on news.

Account

Cerity Partners LLC Bluebird Bio, Inc. Transaction History